Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexFemale
Age18+
SponsorCorcept Therapeutics
About this trial
This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.
Eligibility criteria
Qualifiers
Histologic diagnosis of epithelial ovarian, primary peritoneal, or fallopian-tube carcinoma
Arm A Only: Platinum-resistant disease
Arm B Only: Platinum-sensitive disease who had progression while receiving treatment with a poly(ADP-ribose) polymerase (PARP) inhibitor
Life expectancy of ≥3 months
Disqualifiers
Arm A Only: Has progressed while receiving weekly paclitaxel or nab-paclitaxel
Prior enrollment in a clinical trial of relacorilant
Prior anticancer therapy related toxicities not resolved to grade ≤1
Any surgery within 4 weeks prior to enrollment
Trial design
Treatments tested in this trial
- Relacorilant 150 mg once daily (QD)
- Nab-paclitaxel 80 mg/m^2
- Bevacizumab 10 mg/kg
Treatment groups
270 Participants
are divided into 3 treatment groupsLocations
49Belgium
3289300, Aalst Belgium
3266000, Charleroi Belgium
3253500, Hasselt Belgium
1083000, Leuven Belgium
Sponsors and collaborators
Corcept Therapeutics
Lead sponsor
Source ClinicalTrials.gov